Sponsor: MUSC
Sponsor Study ID: 103919
Study Title: Autophagy Maintenance (AUTOMAIN) Therapy in High-Grade Serous Ovarian Cancer: A Phase II Randomized Trial
CTO #: 103919
NCT Number: NCT06971744
Phase: II
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Ovary
Study Objectives: To assess the safety of HCQ + NFV in combination with standard- of-care maintenance bevacizumab in patients with high-grade serous ovarian cancer. Evaluate the anti-tumor activity of HCQ + NFV in combination with standard-of-care maintenance bevacizumab in patients with high- grade serous ovarian cancer. To assess changes in CA125 in patients treated with HCQ + NFV in combination with standard-of-care maintenance bevacizumab. To assess changes in Quality of Life (QOL) in patients treated with HCQ + NFV in combination with standard-of-care maintenance bevacizumab.